Phase IB/II Study of Lenalidomide and Ibrutinib with R-MPV in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Aged 18-65

The primary objective of this study is to evaluate the efficacy and safety of escalating doses of **Lenalidomide** and **Ibrutinib** in combination with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with newly diagnosed **Primary Central Nervous System Lymphoma (PCNSL)**. This is clinically relevant as it aims to improve treatment outcomes and provide a more effective therapeutic strategy for this aggressive form of lymphoma, which is confined to the central nervous system and poses significant treatment challenges.

The clinical trial involves participants diagnosed with **Primary Central Nervous System Lymphoma (PCNSL)**. The study population includes both male and female subjects, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of escalating doses of **Lenalidomide** and **Ibrutinib** in combination with R-MPV as a targeted induction treatment for patients aged 18 to 60, extending up to 65 for phase II, with newly diagnosed **Primary Central Nervous System Lymphoma (PCNSL)**. This study is structured as a randomized, controlled, double-blind trial, ensuring that neither the participants nor the investigators are aware of the treatment allocations, thereby minimizing bias. The trial commenced on October 30, 2020, and is projected to conclude by October 30, 2034, encompassing a comprehensive duration to assess long-term outcomes.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the participants' response to the treatment, assess any adverse effects, and ensure adherence to the protocol. These visits are critical for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall impact of the treatment regimen.

The expected length of participant involvement will vary depending on individual response and the phase of the trial they are enrolled in. However, participants are anticipated to be involved for a significant portion of the trial's duration to allow for thorough evaluation of the treatment's efficacy and safety. Conditions that may lead to early termination from the study include the occurrence of severe adverse events, withdrawal of consent, or any other medical or ethical reasons deemed necessary by the investigators. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding and potential treatment of **Primary Central Nervous System Lymphoma**.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 7, indicating an advanced stage of clinical research. The estimated recruitment start date was October 30, 2020, with an anticipated end date of October 30, 2034. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's effectiveness. The trial's duration and phase suggest a comprehensive approach to evaluating the intervention's impact on the targeted medical condition. The methodology for measuring and analyzing efficacy will adhere to standard clinical trial protocols, ensuring the reliability and validity of the findings.